Aspirin use and pancreatic cancer risk

European Journal of Cancer Prevention

Volumn 19, Issue 5, 2010, Pages 352-354

  Bonifazi, Martina ^a   Gallus, Silvano ^a   Bosetti, Cristina ^a   Polesel, Jerry ^c   Serraino, Diego ^c   Talamini, Renato ^c   Negri, Eva ^a   La Vecchia, Carlo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

aspirin; case control study; pancreatic cancer; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT DURATION; CLINICAL TRIAL; ITALY; MIDDLE AGED; MULTICENTER STUDY; PANCREATIC NEOPLASMS; RISK; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK; TIME FACTORS;

EID: 77955282124     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833b48a4     Document Type: Article

References (27)

1. Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002). Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94:1168-1171. (Pubitemid 34919054)
2. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357:539-545.
3. Bansal P, Sonnenberg A (1995). Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 109:247-251.
4. Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C (2001). Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 54:902-906.
5. Bosetti C, Gallus S, La Vecchia C (2006). Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871-888.
6. Breslow NE, Day NE (1980). Statistical methods in cancer research. Volume I-The analysis of case-control studies. Lyon, France: IARC Sci Publ. N. 32, 5-338.
7. Capurso G, Schunemann HJ, Terrenato I, Moretti A, Koch M, Muti P, et al. (2007). Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 26:1089-1099.
8. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. (1993). Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311.
9. Hart AR, Kennedy H, Harvey I (2008). Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol 6:275-282.
10. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005). Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076-2083.
11. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008). Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393:535-545.
12. Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ (2004). Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 96:524-528.
13. Kelly JP, Rosenberg L, Kaufman DW, Shapiro S (1990). Reliability of personal interview data in a hospital-based case-control study. Am J Epidemiol 131:79-90.
14. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. (2009). Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol [Epub ahead of print].
15. Larsson SC, Giovannucci E, Bergkvist L,Wolk A (2006). Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:2561-2564.
16. Menezes RJ, Huber KR, Mahoney MC, Moysich KB (2002). Regular use of aspirin and pancreatic cancer risk. BMC Public Health 2:18.
17. Permuth-Wey J, Egan KM (2009). Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8:109-117.
18. Perugini RA, McDade TP, Vittimberga FJ Jr, Duffy AJ, Callery MP (2000). Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines. J Gastrointest Surg 4:24-32. Discussion 32-123
19. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004). Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24:3177-3184.
20. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, (2009). EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45:931-991.
21. Schreinemachers DM, Everson RB (1994). Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146.
22. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, et al. (2004). A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22-28. (Pubitemid 38180956)
23. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, et al. (1990). Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 11:393-395.
24. Talamini R, Polesel J, Gallus S, Dal Maso L, Zucchetto A, Negri E, et al. (2010). Tobacco smoking, alcohol consumption and pancreatic cancer risk: a casecontrol study in Italy. Eur J Cancer 46:370-376.
25. Thun MJ, Henley SJ, Patrono C (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266.
26. Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. (2010). Alcohol drinking and pancreatic cancer risk: A meta-analysis of the dose-risk relation. Int J Cancer 126:1474-1486.
27. Williams CS, Mann M, DuBois RN (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916.